We are live on ! Find out more
ACM

Asymmetry Capital Management Portfolio holdings

AUM $188M
1-Year Est. Return 44.72%
This Fund
S&P 500
This Quarter Est. Return
+12.16%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$188M
AUM Growth
+$22M
Cap. Flow
+$15.2M
Cap. Flow %
8.05%
Top 10 Hldgs %
64.3%
Holding
38
New
9
Increased
8
Reduced
7
Closed
14

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$14.7M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$12.3M
3
UNH icon
UnitedHealth
UNH
+$12.2M
4
IQV icon
IQVIA
IQV
+$11.5M
5
ABBV icon
AbbVie
ABBV
+$11.2M

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$11.5M
2
MDT icon
Medtronic
MDT
+$10.5M
3
PODD icon
Insulet
PODD
+$10.4M
4
HOLX
Hologic
HOLX
+$10.3M
5
SAGE
Sage Therapeutics
SAGE
+$10.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.63%
2 Financials 0.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVTX icon
26
Avalo Therapeutics
AVTX
$1.05B
– –
-186
Closed -$1.17M
AZN icon
27
AstraZeneca
AZN
$252B
– –
-58,121
Closed -$6.98M
BAX icon
28
Baxter International
BAX
$13.5B
– –
-61,570
Closed -$4.95M
HOLX
29
DELISTED
Hologic
HOLX
– –
-138,884
Closed -$10.3M
IRON icon
30
Disc Medicine
IRON
$3.07B
– –
-9,469
Closed -$1.15M
KYMR icon
31
Kymera Therapeutics
KYMR
$9.82B
– –
-89,071
Closed -$5.23M
LRMR icon
32
Larimar Therapeutics
LRMR
$417M
– –
-34,943
Closed -$403K
MDT icon
33
Medtronic
MDT
$117B
– –
-83,737
Closed -$10.5M
PODD icon
34
Insulet
PODD
$10.1B
– –
-36,732
Closed -$10.4M
PTCT icon
35
PTC Therapeutics
PTCT
$5.85B
– –
-215,985
Closed -$8.04M
RNAM
36
DELISTED
Avidity Biosciences
RNAM
– –
-126,116
Closed -$3.11M
SAGE
37
DELISTED
Sage Therapeutics
SAGE
– –
-229,117
Closed -$10.2M
ARNA
38
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-150,001
Closed -$8.93M
1
2

Similar funds

FAC
Forrestal Agricultural Corporation Princeton, New Jersey $183M AUM
SWM
Strategic Wealth Management Kirkland, Washington $202M AUM 9.35% 1-Year Est. Return
MC
MRJ Capital New York $173M AUM 31.99% 1-Year Est. Return
KM
Kylin Management New York $173M AUM 39.51% 1-Year Est. Return
TI
Truehand Inc Strafford, New Hampshire $171M AUM 25.9% 1-Year Est. Return
GC
Grace Capital Quincy, Massachusetts $168M AUM 21.6% 1-Year Est. Return
REMS
Real Estate Management Services $167M AUM 37.69% 1-Year Est. Return
NM
Nokota Management New York $165M AUM

Asymmetry Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Asymmetry Capital Management held 38 positions worth $188M, up 13% from $166M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Asymmetry Capital Management deployed $15.2M of net new capital in Q4 2021, opening 9 new positions and adding to 8 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 177,741 shares worth $15.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was DICE Therapeutics, Inc. Common Stock, an estimated $2.64M trimmed.

  • Asymmetry Capital Management's largest Q4 2021 buy was BioMarin Pharmaceuticals: 177,741 shares worth $15.7M.
  • Asymmetry Capital Management added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2021, an estimated $12.3M increase.
  • Asymmetry Capital Management's biggest Q4 2021 reduction was DICE Therapeutics, Inc. Common Stock, cutting an estimated $2.64M.
  • Asymmetry Capital Management fully exited Alkermes in Q4 2021, selling an estimated $11.5M.
  • Asymmetry Capital Management's ten largest holdings make up 64% of its $188M portfolio in Q4 2021.
  • Asymmetry Capital Management opened 9 new positions and closed 14 in Q4 2021.
  • Asymmetry Capital Management's portfolio value rose 13% quarter-over-quarter to $188M.

Based on Asymmetry Capital Management's 13F filing for Q4 2021, filed 19 Jan 2022.